<DOC>
	<DOCNO>NCT02196064</DOCNO>
	<brief_summary>To evaluate incidence grade 3 4 transaminase elevation grade 4 total bilirubin elevation ( hepatic toxicity ) first 48 week antiretroviral therapy combination rilpivirine ( 25mg ) , tenofovir ( 245mg ) emtricitabine ( 200mg ) , single-tablet regimen ( Eviplera® ) human immunodeficiency virus ( HIV ) /hepatitis C virus ( HCV ) -coinfected subject .</brief_summary>
	<brief_title>Hepatic Safety Eviplera® HIV/Hepatitis C ( HCV ) -Coinfected Patients Without HCV Treatment `` The HEPAVIR HEPATIC SAFETY Cohort . ''</brief_title>
	<detailed_description>This retrospective analysis prospective multicenter , observational `` HEPAVIR HEPATIC SAFETY Cohort '' ( NCT01908660 ) , hepatic safety three-drug combination TDF/FTC/RPV assess . A total 176 patient include study , well 352 patient naive RPV initiate ART include RPV , serve control group . The main objective evaluate incidence grade 3 4 transaminase elevation grade 4 total bilirubin elevation ( hepatic toxicity ) first 48 week antiretroviral therapy combination rilpivirine ( 25mg ) , tenofovir ( 245mg ) emtricitabine ( 200mg ) , single-tablet regimen ( Eviplera® ) human immunodeficiency virus ( HIV ) /hepatitis C virus ( HCV ) -coinfected subject . Variables collect within cohort : - Demographic variable : age , sex . - Variables relate hepatitis C virus-infection : infection route , genotype , grade hepatic fibrosis method use determination , baseline Child-Pugh index patient cirrhosis , previous hepatic decompensations . - Variables relate HIV-infection : CDC clinical category , HIV viral load , CD4 cell count , previous new antiretroviral drug . - Blood test : AST , ALT platelet , cholesterol , bilirubin , gamma-glutamyltransferase , alkaline phosphatase , creatinine . - Other variable : alcohol intake , self-reported adverse event , abnormal clinical finding . - Cause discontinue antiviral applicable . Endpoints 1 . Primary endpoint : Emergence grade 3-4 TEs/grade 4 TBEs ( hepatic toxicity ) baseline week 48 . 2 . Secondary endpoint - Emergence hepatic adverse event . - Drug interruption due liver toxicity . - Development hepatic decompensations . - CD4 viral load change baseline week 48 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>≥ 18 year old . Chronic HIV1 infection , diagnosed basis presence serum HIV antibody detect EIA westernblot . Chronic HCV infection proven detect HCV antibody plasma , well detectable plasma HCVRNA PCR . To start new ART regimen study period . Subjects hepatotoxic event 2 month previous Eviplera® treatment . Acute infection uncontrolled chronic infection two month previous Eviplera® treatment . Concomitant use drug potential drugdrug interaction Eviplera® . Documented resistance study drug . Concomitant therapy include antiHCV agent , cytotoxic chemotherapy immunosuppressor Eviplera® treatment . Subjects take part clinical trial use investigational product , exception study treatment study stop 12 week Eviplera® treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HIV HCV antiretroviral</keyword>
</DOC>